Top

Published in:

2018 | OriginalPaper | Chapter

4. Therapeutics in Neurodegenerative Disorders: Emerging Compounds of Interest

Authors : G. Nagesh Babu, Manjeet Gupta

Published in: Emerging Trends in Chemical Sciences

Publisher: Springer International Publishing

Activate our intelligent search to find suitable subject content or patents.

search-config

AI-assisted search

Off

Abstract

Neurodegenerative diseases are a heterogeneous group of disorders. They are characterized by progressive degeneration of the structure and function of the central nervous system or peripheral nervous system. Neurodegenerative diseases include Parkinson’s Disease (PD), Alzheimer’s Disease (AD), Amyotrophic Lateral Sclerosis (ALS) and Huntington’s Disease (HD). Key characteristic feature of neurodegenerative diseases is aggregation of misfolded proteins in the cytoplasm and nucleus of central nervous system (CNS) neurons. In this review we discuss about the emerging therapeutic compounds and targets for treating these devastating neurological disorders. Oxidative stress appears to be a common denominator and transcription factors are also involved. Compounds that can scavenge free radicals showed some potential. Some protein and peptide compounds also exhibited good therapeutic activity. Ligand binding domains are targeted for efficacy and showed promise. Agonists and antagonists of receptors and enzyme inhibitors are playing a remarkable role in controlling the symptoms of these diseases. Chemical chaperones and compounds that can inhibit the protein aggregation are widely tried and showing therapeutic potential.

Dont have a licence yet? Then find out more about our products and how to get one now:

Springer Professional "Wirtschaft+Technik"

Online-Abonnement

Mit Springer Professional "Wirtschaft+Technik" erhalten Sie Zugriff auf:

über 102.000 Bücher
über 537 Zeitschriften

aus folgenden Fachgebieten:

Automobil + Motoren
Bauwesen + Immobilien
Business IT + Informatik
Elektrotechnik + Elektronik
Energie + Nachhaltigkeit
Finance + Banking
Management + Führung
Marketing + Vertrieb
Maschinenbau + Werkstoffe
Versicherung + Risiko

Jetzt Wissensvorsprung sichern!

inform now

Springer Professional "Technik"

Online-Abonnement

Mit Springer Professional "Technik" erhalten Sie Zugriff auf:

über 67.000 Bücher
über 390 Zeitschriften

aus folgenden Fachgebieten:

Automobil + Motoren
Bauwesen + Immobilien
Business IT + Informatik
Elektrotechnik + Elektronik
Energie + Nachhaltigkeit
Maschinenbau + Werkstoffe

Jetzt Wissensvorsprung sichern!

inform now

previous chapter Chemical Composition and Antioxidant Activity of Tagetes minuta L. in Eastern Cape, South Africa

next chapter Investigation of Heavy Metal Hazards Status and Their Potential Health Risks in Vegetables Irrigated with Treated Wastewater in Oodi Gardens

Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E (2003) Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 24:197–211CrossRef

Rodriguez-Oroz MC, Jahanshahi M, Krack P, Litvan I, Macias R, Bezard E, Obeso JA (2009) Initial clinical manifestations of Parkinson’s disease: features and pathophysiological mechanisms. Lancet Neurol 8:1128–1139CrossRef

Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M (1997) Alpha-synuclein in Lewy bodies. Nature 388:839–840CrossRef

Lim KL, Zhang CW (2013) Molecular events underlying Parkinson’s disease—an interwoven tapestry. Front Neurol 4:33CrossRef

Schapira AH, Jenner P (2011) Etiology and pathogenesis of Parkinson’s disease. Mov Disord 26:1049–1055CrossRef

Halliwell B (1992) Reactive oxygen species and the central nervous system. J Neurochem 59:1609–1623CrossRef

Hwang O (2013) Role of oxidative stress in Parkinson’s disease. Exp Neurobiol 22:11–17CrossRef

Kumar A, Singh RL, Babu GN (2010) Cell death mechanisms in the early stages of acute glutamate neurotoxicity. Neurosci Res 66:271–278CrossRef

Babu GN, Kumar A, Singh RL (2011) Chronic pretreatment with acetyl-L-carnitine and +/-DL-alpha-lipoic acid protects against acute glutamate-induced neurotoxicity in rat brain by altering mitochondrial function. Neurotox Res 19:319–329CrossRef

10.

Luo J, Lee SH, VandeVrede L, Qin Z, Piyankarage S, Tavassoli E, Asghodom RT, Ben Aissa M, Fa M, Arancio O, Yue L, Pepperberg DR, Thatcher GR (2015) Re-engineering a neuroprotective, clinical drug as a procognitive agent with high in vivo potency and with GABAA potentiating activity for use in dementia. BMC Neurosci 16:67CrossRef

11.

Procaccini C, Santopaolo M, Faicchia D, Colamatteo A, Formisano L, de Candia P, Galgani M, De Rosa V, Matarese G (2016) Role of metabolism in neurodegenerative disorders. Metabolism 65:1376–1390CrossRef

12.

Babu GN, Kumar A, Chandra R, Puri SK, Kalita J, Misra UK (2008) Elevated inflammatory markers in a group of amyotrophic lateral sclerosis patients from northern India. Neurochem Res 33:1145–1149CrossRef

13.

Babu GN, Kumar A, Chandra R, Puri SK, Singh RL, Kalita J, Misra UK (2008) Oxidant-antioxidant imbalance in the erythrocytes of sporadic amyotrophic lateral sclerosis patients correlates with the progression of disease. Neurochem Int 52:1284–1289CrossRef

14.

Kumar A, Bala L, Kalita J, Misra UK, Singh RL, Khetrapal CL (2010) Metabolomic analysis of serum by (1) H NMR spectroscopy in amyotrophic lateral sclerosis. Clin Chim Acta 411:563–567CrossRef

15.

Mollica PA, Reid JA, Ogle RC, Sachs PC, Bruno RD (2016) DNA methylation leads to DNA repair gene down-regulation and trinucleotide repeat expansion in patient-derived Huntington disease cells. Am J Pathol 186:1967–1976CrossRef

16.

Gauthier LR, Charrin BC, Borrell-Pages M, Dompierre JP, Rangone H, Cordelieres FP, De Mey J, MacDonald ME, Lessmann V, Humbert S, Saudou F (2004) Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell 118:127–138CrossRef

17.

Rizza S, Cirotti C, Montagna C, Cardaci S, Consales C, Cozzolino M, Carri MT, Cecconi F, Filomeni G (2015) S-nitrosoglutathione reductase plays opposite roles in SH-SY5Y models of Parkinson’s disease and amyotrophic lateral sclerosis. Mediators Inflamm 2015:536238CrossRef

18.

Joshi G, Johnson JA (2012) The NRF-2 ARE pathway: a valuable therapeutic target for the treatment of neurodegenerative diseases. Recent Pat CNS Drug Discov 7:218–229CrossRef

19.

Kim CH, Han BS, Moon J, Kim DJ, Shin J, Rajan S, Nguyen QT, Sohn M, Kim WG, Han M, Jeong I, Kim KS, Lee EH, Tu Y, Naffin-Olivos JL, Park CH, Ringe D, Yoon HS, Petsko GA, Kim KS (2015) Nuclear receptor Nurr1 agonists enhance its dual functions and improve behavioral deficits in an animal model of Parkinson’s disease. Proc Natl Acad Sci USA 112:8756–8761CrossRef

20.

Cortesi R, Esposito E, Drechsler M, Pavoni G, Cacciatore I, Sguizzato M, Di Stefano A (2017) Levodopa co-drugs in nanostructured lipid carriers: a comparative study. Mater Sci Eng C Mater Biol Appl 72:168–176CrossRef

21.

Cattaneo C, Sardina M, Bonizzoni E (2016) Safinamide as add-on therapy to levodopa in mid- to late-stage Parkinson’s disease fluctuating patients: post hoc analyses of studies 016 and SETTLE. J Parkinsons Dis 6:165–173CrossRef

22.

Lees AJ, Ferreira J, Rascol O, Poewe W, Rocha JF, McCrory M, Soares-da-Silva P, Investigators B-S (2016) Opicapone as adjunct to levodopa therapy in patients with Parkinson’s disease and motor fluctuations: a randomized clinical trial. JAMA Neurol 74(2):197–206. doi:10.1001/jamaneurol.2016.4703 CrossRef

23.

Senek M, Nielsen EI, Nyholm D (2016) Levodopa-entacapone-carbidopa intestinal gel in Parkinson’s disease: a randomized crossover study. Mov Disord 32(2):283–286. doi:10.1002/mds.26855 CrossRef

24.

Rossi C, Genovesi D, Marzullo P, Giorgetti A, Filidei E, Corsini GU, Bonuccelli U, Ceravolo R (2016) Striatal dopamine transporter modulation after rotigotine: results from a pilot single-photon emission computed tomography study in a group of early stage Parkinson disease patients. Clin Neuropharmacol 40(1):34–36. doi:10.1097/WNF.0000000000000198

25.

Trenkwalder C, Stocchi F, Poewe W, Dronamraju N, Kenney C, Shah A, von Raison F, Graf A (2016) Mavoglurant in Parkinson’s patients with Levodopa-induced dyskinesias: two randomized phase 2 studies. Mov Disord 31:1054–1058CrossRef

26.

Pinna A, Ko WK, Costa G, Tronci E, Fidalgo C, Simola N, Li Q, Tabrizi MA, Bezard E, Carta M, Morelli M (2016) Antidyskinetic effect of A2A and 5HT1A/1B receptor ligands in two animal models of Parkinson’s disease. Mov Disord 31:501–511CrossRef

27.

Svenningsson P, Rosenblad C, Af Edholm Arvidsson K, Wictorin K, Keywood C, Shankar B, Lowe DA, Bjorklund A, Widner H (2015) Eltoprazine counteracts Levodopa-induced dyskinesias in Parkinson’s disease: a dose-finding study. Brain 138:963–973CrossRef

28.

Paolone G, Brugnoli A, Arcuri L, Mercatelli D, Morari M (2015) Eltoprazine prevents levodopa-induced dyskinesias by reducing striatal glutamate and direct pathway activity. Mov Disord 30:1728–1738CrossRef

29.

Pereira NA, Sureda FX, Perez M, Amat M, Santos MM (2016) Enantiopure indolo[2,3-a]quinolizidines: synthesis and evaluation as NMDA receptor antagonists. Molecules 21:1027CrossRef

30.

van der Walt MM, Terre'Blanche G (2017) Selected C8 two-chain linkers enhance the adenosine A1/A2A receptor affinity and selectivity of caffeine. Eur J Med Chem 125:652–656CrossRef

31.

Moccia M, Erro R, Picillo M, Vitale C, Longo K, Amboni M, Pellecchia MT, Barone P (2016) Caffeine consumption and the 4-year progression of de novo Parkinson’s disease. Parkinsonism Relat Disord 32:116–119CrossRef

32.

Robinson SJ, Petzer JP, Terre'Blanche G, Petzer A, van der Walt MM, Bergh JJ, Lourens AC (2015) 2-Aminopyrimidines as dual adenosine A1/A2A antagonists. Eur J Med Chem 104:177–188CrossRef

33.

Van der Walt MM, Terre'Blanche G, Petzer A, Petzer JP (2015) The adenosine receptor affinities and monoamine oxidase B inhibitory properties of sulfanylphthalimide analogues. Bioorg Chem 59:117–123CrossRef

34.

Li Z, Wang P, Yu Z, Cong Y, Sun H, Zhang J, Zhang J, Sun C, Zhang Y, Ju X (2015) The effect of creatine and coenzyme q10 combination therapy on mild cognitive impairment in Parkinson’s disease. Eur Neurol 73:205–211CrossRef

35.

Yoritaka A, Kawajiri S, Yamamoto Y, Nakahara T, Ando M, Hashimoto K, Nagase M, Saito Y, Hattori N (2015) Randomized, double-blind, placebo-controlled pilot trial of reduced coenzyme Q10 for Parkinson’s disease. Parkinsonism Relat Disord 21:911–916CrossRef

36.

Breydo L, Newland B, Zhang H, Rosser A, Werner C, Uversky VN, Wang W (2016) A hyperbranched dopamine-containing PEG-based polymer for the inhibition of alpha-synuclein fibrillation. Biochem Biophys Res Commun 469:830–835CrossRef

37.

Aasly JO, Saether O, Johansen KK, Bathen TF, Giskeodegard GF, White LR (2015) Changes to intermediary metabolites in sporadic and LRRK2 Parkinson’s disease demonstrated by proton magnetic resonance spectroscopy. Parkinsons Dis 2015:264896

38.

Games D, Valera E, Spencer B, Rockenstein E, Mante M, Adame A, Patrick C, Ubhi K, Nuber S, Sakayon P, Zago W, Seubert P, Barbour R, Schenk D, Masliah E (2014) Reducing C-terminal-truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinson’s disease-like models. J Neurosci 34:9441–9454CrossRef

39.

Ariga H, Takahashi-Niki K, Kato I, Maita H, Niki T, Iguchi-Ariga SM (2013) Neuroprotective function of DJ-1 in Parkinson’s disease. Oxid Med Cell Longev 2013:683920CrossRef

40.

Lev N, Barhum Y, Ben-Zur T, Aharony I, Trifonov L, Regev N, Melamed E, Gruzman A, Offen D (2015) A DJ-1 based peptide attenuates dopaminergic degeneration in mice models of Parkinson’s disease via enhancing Nrf2. PLoS One 10:e0127549CrossRef

41.

Glat MJ, Ben-Zur T, Barhum Y, Offen D (2016) Neuroprotective effect of a DJ-1 based peptide in a toxin induced mouse model of multiple system atrophy. PLoS One 11:e0148170CrossRef

42.

Takahashi-Niki K, Inafune A, Michitani N, Hatakeyama Y, Suzuki K, Sasaki M, Kitamura Y, Niki T, Iguchi-Ariga SM, Ariga H (2015) DJ-1-dependent protective activity of DJ-1-binding compound no. 23 against neuronal cell death in MPTP-treated mouse model of Parkinson’s disease. J Pharmacol Sci 127:305–310CrossRef

43.

Khan MM, Zaheer S, Nehman J, Zaheer A (2014) Suppression of glia maturation factor expression prevents 1-methyl-4-phenylpyridinium (MPP(+))-induced loss of mesencephalic dopaminergic neurons. Neuroscience 277:196–205CrossRef

44.

Luk B, Mohammed M, Liu F, Lee FJ (2015) A physical interaction between the dopamine transporter and DJ-1 facilitates increased dopamine reuptake. PLoS One 10:e0136641CrossRef

45.

Bhattacharyya S, Bakshi R, Logan R, Ascherio A, Macklin EA, Schwarzschild MA (2016) Oral inosine persistently elevates plasma antioxidant capacity in Parkinson’s disease. Mov Disord 31:417–421CrossRef

46.

Frakey LL, Friedman JH (2016) Cognitive effects of Rasagiline in mild-to-moderate stage Parkinson’s disease without dementia. J Neuropsychiatry Clin Neurosci 29(1):22–25. doi:10.1176/appi.neuropsych.15050118 CrossRef

47.

Murata M, Hasegawa K, Kanazawa I, Fukasaka J, Kochi K, Shimazu R, Japan Zonisamide on PDSG (2015) Zonisamide improves wearing-off in Parkinson’s disease: a randomized, double-blind study. Mov Disord 30:1343–1350CrossRef

48.

Zhou R, Shi XY, Bi DC, Fang WS, Wei GB, Xu X (2015) Alginate-derived oligosaccharide inhibits neuroinflammation and promotes microglial phagocytosis of beta-amyloid. Mar Drugs 13:5828–5846CrossRef

49.

Trushina E, Zhang L, Zhang S, Trushin S, Hua D (2015) Mitochondria-targeted therapeutics for Alzheimer’s disease. J Neurol Sci 357:e7–e9CrossRef

50.

Fisher A, Bezprozvanny I, Ryskamp D, Frenkel D, Rabinovich A, Bar-Ner N, Natan N, Brandeis R, Elkon H, Gershonov E, Laferla F, Mederios R (2016) A unique target for a comprehensive therapy of Alzheimer’s disease: concomitant activation of sigma1/M1 muscarinic receptors. Neurobiol Aging 39:S5CrossRef

51.

Sheng R, Tang L, Jiang L, Hong L, Shi Y, Zhou N, Hu Y (2016) Novel 1-phenyl-3-hydroxy-4-pyridinone derivatives as multifunctional agents for the therapy of Alzheimer’s disease. ACS Chem Neurosci 7:69–81CrossRef

52.

Baruch K, Rosenzweig N, Kertser A, Deczkowska A, Sharif AM, Spinrad A, Tsitsou-Kampeli A, Sarel A, Cahalon L, Schwartz M (2015) Breaking immune tolerance by targeting Foxp3(+) regulatory T cells mitigates Alzheimer’s disease pathology. Nat Commun 6:7967CrossRef

53.

Panza F, Solfrizzi V, Seripa D, Imbimbo BP, Lozupone M, Santamato A, Zecca C, Barulli MR, Bellomo A, Pilotto A, Daniele A, Greco A, Logroscino G (2016) Tau-centric targets and drugs in clinical development for the treatment of Alzheimer’s disease. Biomed Res Int:3245935. doi:10.1155/2016/3245935

54.

Makhaeva GF, Lushchekina SV, Boltneva NP, Sokolov VB, Grigoriev VV, Serebryakova OG, Vikhareva EA, Aksinenko AY, Barreto GE, Aliev G, Bachurin SO (2015) Conjugates of gamma-carbolines and phenothiazine as new selective inhibitors of butyrylcholinesterase and blockers of NMDA receptors for Alzheimer disease. Sci Rep 5:13164CrossRef

55.

Grimaldi M, Marino SD, Florenzano F, Ciotta MT, Nori SL, Rodriquez M, Sorrentino G, D'Ursi AM, Scrima M (2016) beta-Amyloid-acetylcholine molecular interaction: new role of cholinergic mediators in anti-Alzheimer therapy? Future Med Chem 8:1179–1189CrossRef

56.

Dgachi Y, Ismaili L, Knez D, Benchekroun M, Martin H, Szalaj N, Wehle S, Bautista-Aguilera OM, Luzet V, Bonnet A, Malawska B, Gobec S, Chioua M, Decker M, Chabchoub F, Marco-Contelles J (2016) Synthesis and biological assessment of racemic benzochromenopyrimidinimines as antioxidant, cholinesterase, and Aβ1-42 aggregation inhibitors for Alzheimer’s disease therapy. Chem Med Chem 11:1318–1327CrossRef

57.

Kumar J, Meena P, Singh A, Jameel E, Maqbool M, Mobashir M, Shandilya A, Tiwari M, Hoda N, Jayaram B (2016) Synthesis and screening of triazolopyrimidine scaffold as multi-functional agents for Alzheimer’s disease therapies. Eur J Med Chem 119:260–277CrossRef

58.

Smilansky A, Dangoor L, Nakdimon I, Ben-Hail D, Mizrachi D, Shoshan-Barmatz V (2015) The voltage-dependent anion channel 1 mediates amyloid beta toxicity and represents a potential target for Alzheimer disease therapy. J Biol Chem 290:30670–30683CrossRef

59.

Gejl M, Gjedde A, Egefjord L, Moller A, Hansen SB, Vang K, Rodell A, Braendgaard H, Gottrup H, Schacht A, Moller N, Brock B, Rungby J (2016) In Alzheimer’s disease, 6-month treatment with GLP-1 analog prevents decline of brain glucose metabolism: randomized, placebo-controlled, double-blind clinical trial. Front Aging Neurosci 8:108CrossRef

60.

Hinrich AJ, Jodelka FM, Chang JL, Brutman D, Bruno AM, Briggs CA, James BD, Stutzmann GE, Bennett DA, Miller SA, Rigo F, Marr RA, Hastings ML (2016) Therapeutic correction of ApoER2 splicing in Alzheimer’s disease mice using antisense oligonucleotides. EMBO Mol Med 8:328–345CrossRef

61.

Pereira PA, Tomas JF, Queiroz JA, Figueiras AR, Sousa F (2016) Recombinant pre-miR-29b for Alzheimer’s disease therapeutics. Sci Rep 6:19946CrossRef

62.

Nagata E, Ogino M, Iwamoto K, Kitagawa Y, Iwasaki Y, Yoshii F, Ikeda JE, ALS Consortium Investigators (2016) Bromocriptine mesylate attenuates amyotrophic lateral sclerosis: a phase 2a, randomized, double-blind, placebo-controlled research in Japanese patients. PLoS One 11:e0152845CrossRef

63.

Naujock M, Stanslowsky N, Bufler S, Naumann M, Reinhardt P, Sterneckert J, Kefalakes E, Kassebaum C, Bursch F, Lojewski X, Storch A, Frickenhaus M, Boeckers TM, Putz S, Demestre M, Liebau S, Klingenstein M, Ludolph AC, Dengler R, Kim KS, Hermann A, Wegner F, Petri S (2016) 4-Aminopyridine induced activity rescues hypoexcitable motor neurons from amyotrophic lateral sclerosis patient-derived induced pluripotent stem cells. Stem Cells 34:1563–1575CrossRef

64.

Getter T, Zaks I, Barhum Y, Ben-Zur T, Boselt S, Gregoire S, Viskind O, Shani T, Gottlieb H, Green O, Shubely M, Senderowitz H, Israelson A, Kwon I, Petri S, Offen D, Gruzman A (2015) A chemical chaperone-based drug candidate is effective in a mouse model of amyotrophic lateral sclerosis (ALS). Chem Med Chem 10:850–861CrossRef

65.

Apolloni S, Fabbrizio P, Parisi C, Amadio S, Volonte C (2016) Clemastine confers neuroprotection and induces an anti-inflammatory phenotype in SOD1(G93A) mouse model of amyotrophic lateral sclerosis. Mol Neurobiol 53:518–531CrossRef

66.

Elia AE, Lalli S, Monsurro MR, Sagnelli A, Taiello AC, Reggiori B, La Bella V, Tedeschi G, Albanese A (2016) Tauroursodeoxycholic acid in the treatment of patients with amyotrophic lateral sclerosis. Eur J Neurol 23:45–52CrossRef

67.

Seredenina T, Nayernia Z, Sorce S, Maghzal GJ, Filippova A, Ling SC, Basset O, Plastre O, Daali Y, Rushing EJ, Giordana MT, Cleveland DW, Aguzzi A, Stocker R, Krause KH, Jaquet V (2016) Evaluation of NADPH oxidases as drug targets in a mouse model of familial amyotrophic lateral sclerosis. Free Radic Biol Med 97:95–108CrossRef

68.

Isobe T, Tooi N, Nakatsuji N, Aiba K (2015) Amyotrophic lateral sclerosis models derived from human embryonic stem cells with different superoxide dismutase 1 mutations exhibit differential drug responses. Stem Cell Res 15:459–468CrossRef

69.

Bellouze S, Baillat G, Buttigieg D, de la Grange P, Rabouille C, Haase G (2016) Stathmin 1/2-triggered microtubule loss mediates Golgi fragmentation in mutant SOD1 motor neurons. Mol Neurodegener 11:43CrossRef

70.

Cai M, Yang EJ (2016) Ginsenoside reattenuates neuroinflammation in a symptomatic ALS animal model. Am J Chin Med 44:401–413CrossRef

71.

Akamatsu M, Yamashita T, Hirose N, Teramoto S, Kwak S (2016) The AMPA receptor antagonist perampanel robustly rescues amyotrophic lateral sclerosis (ALS) pathology in sporadic ALS model mice. Sci Rep 6:28649CrossRef

72.

Zeng Y, Guo W, Xu G, Wang Q, Feng L, Long S, Liang F, Huang Y, Lu X, Li S, Zhou J, Burgunder JM, Pang J, Pei Z (2016) Xyloketal-derived small molecules show protective effect by decreasing mutant huntingtin protein aggregates in Caenorhabditis elegans model of Huntington’s disease. Drug Des Devel Ther 10:1443–1451CrossRef

73.

Zielonka D, Mielcarek M, Landwehrmeyer GB (2015) Update on Huntington’s disease: advances in care and emerging therapeutic options. Parkinsonism Relat Disord 21:169–178CrossRef

74.

Yin X, Manczak M, Reddy PH (2016) Mitochondria-targeted molecules MitoQ and SS31 reduce mutant huntingtin-induced mitochondrial toxicity and synaptic damage in Huntington’s disease. Hum Mol Genet 25:1739–1753CrossRef

75.

Marelli C, Maschat F (2016) The P42 peptide and peptide-based therapies for Huntington’s disease. Orphanet J Rare Dis 11:24CrossRef

76.

Sassone F, Margulets V, Maraschi A, Rodighiero S, Passafaro M, Silani V, Ciammola A, Kirshenbaum LA, Sassone JF (2015) Bcl-2/adenovirus E1B 19-kDa interacting protein (BNip3) has a key role in the mitochondrial dysfunction induced by mutant huntingtin. Hum Mol Genet 24:6530–6539CrossRef

77.

Stanek LM, Sardi SP, Mastis B, Richards AR, Traleaven CM, Tatyana T, Misra K, Cheng SH, Shihabuddin LS (2014) Silencing mutant huntingtin by adeno-associated virus-mediated RNA interference ameliorates disease manifestations in the YAC128 mouse model of Huntington’s Disease. Human Gene Therapy 25:461–474CrossRef

Title: Therapeutics in Neurodegenerative Disorders: Emerging Compounds of Interest
Authors: G. Nagesh Babu
Manjeet Gupta
Publisher: Springer International Publishing
Book: Emerging Trends in Chemical Sciences
Print ISBN: 978-3-319-60407-7

Electronic ISBN: 978-3-319-60408-4

Copyright Year: 2018
DOI: https://doi.org/10.1007/978-3-319-60408-4_4

Springer Professional

Abstract

Please log in to get access to your license.

Dont have a licence yet? Then find out more about our products and how to get one now:

Springer Professional "Wirtschaft+Technik"

Springer Professional "Technik"

Premium Partners